- Home
- HTH vs MIRM Comparison
HTH vs MIRM Comparison
Compare HTH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- MIRM
- Stock Information
- Founded
- HTH 1998
- MIRM 2018
- Country
- HTH United States
- MIRM United States
- Employees
- HTH N/A
- MIRM N/A
- Industry
- HTH Major Banks
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- HTH Finance
- MIRM Health Care
- Exchange
- HTH Nasdaq
- MIRM Nasdaq
- Market Cap
- HTH 1.9B
- MIRM 2.0B
- IPO Year
- HTH 2004
- MIRM 2019
- Fundamental
- Price
- HTH $28.40
- MIRM $42.00
- Analyst Decision
- HTH Hold
- MIRM Strong Buy
- Analyst Count
- HTH 3
- MIRM 11
- Target Price
- HTH $34.50
- MIRM $57.00
- AVG Volume (30 Days)
- HTH 318.2K
- MIRM 383.6K
- Earning Date
- HTH 01-23-2025
- MIRM 02-26-2025
- Dividend Yield
- HTH 2.38%
- MIRM N/A
- EPS Growth
- HTH N/A
- MIRM N/A
- EPS
- HTH 1.63
- MIRM N/A
- Revenue
- HTH $1,169,826,000.00
- MIRM $307,028,000.00
- Revenue This Year
- HTH N/A
- MIRM $82.14
- Revenue Next Year
- HTH $0.79
- MIRM $26.18
- P/E Ratio
- HTH $17.56
- MIRM N/A
- Revenue Growth
- HTH N/A
- MIRM 112.14
- 52 Week Low
- HTH $28.35
- MIRM $23.14
- 52 Week High
- HTH $35.45
- MIRM $48.89
- Technical
- Relative Strength Index (RSI)
- HTH 34.15
- MIRM 43.08
- Support Level
- HTH $28.35
- MIRM $40.91
- Resistance Level
- HTH $28.98
- MIRM $42.40
- Average True Range (ATR)
- HTH 0.72
- MIRM 1.39
- MACD
- HTH -0.16
- MIRM -0.18
- Stochastic Oscillator
- HTH 10.94
- MIRM 33.52
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. Its primary line of business is to provide business and consumer banking services from offices throughout Texas through the PlainsCapital Bank. The company also provides other financial products and services through its broker-dealer and mortgage origination segments. The company generates a majority of its revenue through its banking operations.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.